University of California, Berkeley-Haas collection. The OncoMed case study illustrates the important challenges confronting a business that pursues new therapies in the biotechnology sector. This is as opposed to me-too or second generation drug companies, for example Proteolix, where the business is attempting to create an improved treatment directed against a target for which there's significant clinical validation (a challenging pursuit as well--find the Proteolix case study, also released at the Berkeley-Haas School of Business).
OncoMed Pharmaceuticals Novel Anti-Cancer Stem Cell Therapeutics Case Study Solution
OncoMed Pharmaceuticals was a clinical phase cancer stem cell (CSC) company founded in August 2004. By 2012, even though the company approved for sale or had no earnings and no product nominees in critical clinical trials, the team had reached significant scientific milestones that led it to file for an initial public offering on May 11, 2012. By that time, OncoMed had another starting later that year, so attaining improbable, partial success as a novel drug development business in the challenging field of biotechnology where success was much surpassed by failure and four clinical trials occurring.
PUBLICATION DATE: August 01, 2012 PRODUCT #: B5726-HCB-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
The Era of Global Solution Networks
Boost M6700 (B): Buyer Seller Negotiation – Confidential Instructions for Cindy Tan
Dengue – Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery
Moving beyond initial success: Promoting innovation in small businesses through high-performance work practices
Lawrence & Mayo Envisioning the Future
Blood Bananas: Chiquita in Colombia
The Pacific LNG Project
Energy Security in Europe (B): The Southern Corridor
Jextra Neighborhood Stores in Malaysia
Insurer of Last Resort?: The Federal Financial Response to September 11
